Empath Ventures

Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutics for psychiatric and neurological disorders, emphasizing non-hallucinogenic and rapid-acting agents. By leveraging psychedelic molecules, Psylo seeks to develop improved medications that provide effective alternatives to existing selective serotonin reuptake inhibitors (SSRIs). Its mission is to enhance treatment options for mood disorders, addiction, and certain neurological conditions, thereby broadening the scope of mental health care.

Aperture Therapeutics is a biotechnology company focused on the development of novel therapies for age-related neurodegenerative diseases. Utilizing a unique drug discovery platform, the company aims to harness the genetic diversity of patients to identify new disease pathways and drug targets. With operations based in a lab incubator, Aperture Therapeutics is in the pre-clinical stage, actively applying insights from neuroscience and immunology to advance its research. The company's approach emphasizes the importance of genetic diversity in the discovery process, aiming to lead to more effective treatments for neurodegeneration and neuroimmunology conditions.

Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.

TARA Mind is a public benefit corporation focused on improving access to psychedelic-assisted therapy for individuals with treatment-resistant depression. The company addresses gaps in therapeutic accessibility and affordability for high-risk mental health patients by offering a supplemental employer benefit that facilitates safe and affordable access to these innovative therapies. TARA Mind has established a network of vetted providers across the United States, equipping them with proprietary digital tools that support measurement-based care. This data-driven approach enables value-based reimbursements, allowing employers to provide effective and legal mental health treatment as part of their insurance benefits, ultimately aiming to enhance the well-being of their workforce.

Nue Life focuses on enhancing mental wellness by improving brain function and overall performance through scientifically validated treatments. The company has developed a comprehensive therapeutic ecosystem that includes at-home ketamine therapy, an interactive companion app, and virtual aftercare programs aimed at supporting individuals in their healing journeys. By utilizing artificial intelligence and knowledge graphs, the app personalizes evidence-based therapies, allowing users to effectively diagnose and address their mental health conditions. Through these innovative approaches, Nue Life seeks to provide accessible and effective mental health solutions.

Motif Neurotech develops minimally invasive bioelectronic implants aimed at monitoring and treating severe mental illnesses, particularly treatment-resistant depression. The company focuses on wireless power and data technologies, which facilitate the creation of new, miniature implants designed for tissue stimulation and diagnostic readings. These innovative implants enable patients to repair neural circuits through electronic therapies, offering a promising approach to address complex mental health challenges.

Superpower is a developer of a digital clinic focused on personalized healthcare solutions. The company's platform provides users with a comprehensive health dashboard and a tailored action plan, along with access to curated tests, products, and protocols. By offering advanced diagnostics and vetted therapeutics, Superpower aims to empower individuals to pursue longer, healthier, and more vital lives. The platform is designed to enhance the management of personal health, making it more convenient and effective for users seeking to improve their overall well-being.

Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutics for psychiatric and neurological disorders, emphasizing non-hallucinogenic and rapid-acting agents. By leveraging psychedelic molecules, Psylo seeks to develop improved medications that provide effective alternatives to existing selective serotonin reuptake inhibitors (SSRIs). Its mission is to enhance treatment options for mood disorders, addiction, and certain neurological conditions, thereby broadening the scope of mental health care.

Pangea Botanica helps to accelerate the discovery and development of therapeutics for patients by using naturally occurring compounds and traditional remedies, while preserving ethnobotanical knowledge and ecosystems. It is a biotechnology research organisation that offers drug discovery and development services.

Freedom Biosciences is a biotechnology platform focused on developing next-generation psychedelic therapeutics. The company aims to create innovative psychedelic pharmaceuticals by utilizing the established pharmacology of ketamine and other psychedelic compounds. This approach is intended to equip medical professionals with effective treatment options for patients suffering from resistant depression and various mental disorders.

Kanna Health is a preclinical stage biotechnology company focused on developing innovative therapeutics derived from kanna, or Sceletium tortuosum, a medicinal succulent used for centuries by the San hunter-gatherers of South Africa. The company aims to address significant unmet needs in sexual and mental health through its lead candidate, KH-001, which is based on alkaloids found in kanna. This candidate is designed to enhance mood and performance in men, offering potential treatments that are both effective and affordable.

Wavepaths is a London-based company established in 2018 that focuses on creating innovative tools for psychedelic therapy aimed at facilitating inner exploration and personal transformation. The company develops a unique application that auto-generates individualized soundtracks for drug-free therapy sessions, integrating immersive media with advancements in intelligent technology and psychedelic science. By combining these elements, Wavepaths offers mobile tools and physical environments designed to help users reconnect with their inner resources, fostering meaningful introspection and emotional reconnection. The company's work lies at the intersection of information technology, healthcare, and personal health, emphasizing accessibility and personal growth through therapeutic experiences.

Beond specializes in providing wellness and healing treatments aimed at addressing addiction and trauma. The company offers treatments using ibogaine to help individuals struggling with chemical dependency, substance abuse, and various behavioral conditions, including anxiety, depression, and PTSD. Through a combination of counseling, education, and support, Beond seeks to facilitate profound transformational life changes for its clients, empowering them to overcome their mental health challenges and achieve recovery.

MycroDose Therapeutics is a U.S.-based pharmaceutical company focused on developing advanced drug delivery systems that utilize psychedelic compounds for the treatment of mental health disorders and cognitive degenerative diseases. The company is actively working on two of its four core technologies, which include a psilocybin transdermal delivery system and a ketamine oral mucosa delivery system. By leveraging these innovative approaches, MycroDose Therapeutics aims to enhance the efficacy and accessibility of treatments for patients dealing with these challenging conditions.

Quantified Citizen is a mobile health research platform that aims to modernize scientific research by making it more accessible to both citizen scientists and professional researchers. The platform allows users to easily create and participate in behavioral studies using standardized health measures. It features a diverse library of research focused on various health interventions, including topics such as psychedelics and micro-dosing for mental health. By fostering a community of contributors, Quantified Citizen facilitates faster insights into health research and encourages broader participation in scientific discovery.